Published in Women's Health Weekly, July 28th, 2005
"The epothilones are a novel class of microtubule-stabilizing agents," oncologists in the United States explained. "Ixabepilone (BMS-247550; NSC 710428) is a semisynthetic analog of the natural product epothilone B."
S.H. Zhuang and colleagues at the National Cancer Institute "conducted a Phase I study by administering ixabepilone to patients as a 1-hour intravenous infusion daily for 3 consecutive days every 21 days."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.